ArticleFrontiers in oncology2026
VA/VHAG alternating consolidation regimen combined with umbilical cord blood and mesenchymal stem cell infusion for the treatment of high-risk MDS patients who are unfit for transplantation: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The only treatment option for high-risk MDS patients unfit for transplantation is continuous treatment with a hypomethylating agent (HMA). In this context, some new combination HMA regimens and other drugs with different mechanisms of action have been developed recently; however, no breakthroughs have been made. In our clinical practice, we have gradually explored various new methods-induction therapy with a modified VIALE-A (VA) regimen and an alternating regimen of modified VA and VHAG for the consolidation period. Some patients who were persistently positive for MRD were treated with HLA-mismatched umbilical cord blood, and patients with poor hematopoietic recovery additionally received mesenchymal stem cells infusion. Together, these treatments showed good efficacy. Here, the total treatment process for a typical patient is described, and a review of the literature is provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.